{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:50:21Z","timestamp":1789775421266,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases globally. Pharmacological treatments for NAFLD are still limited. Silymarin, a compound extracted from <jats:italic>Silybum marianum<\/jats:italic>, is an herbal supplement traditionally used in folk medicine for liver disorders. It has been proposed that silymarin may possess hepatoprotective and anti-inflammatory properties. The present trial aims to assess the efficacy of silymarin supplementation in the adjuvant treatment of NAFLD in adult patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This is a randomized double-blind placebo-controlled clinical trial recruiting adult NAFLD patients in therapy on an outpatient basis. Participants are randomized to an intervention (I) or control (C) group. Both groups receive identical capsules and are followed for 12 weeks. I receives 700mg of silymarin + 8mg vitamin E + 50mg phosphatidylcholine daily, while C receives 700mg maltodextrin + 8mg vitamin E + 50mg phosphatidylcholine daily. Patients undergo a computerized tomography (CT) scan and blood tests at the beginning and end of the study. Monthly face-to-face consultations and weekly telephone contact are carried out for all participants. The primary outcome assessed will be change in NAFLD stage, if any, assessed by the difference in attenuation coefficient between liver and spleen, obtained by upper abdomen CT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of this study may provide a valuable opinion on whether silymarin can be used as adjuvant therapy for the management or treatment of NAFLD. The data presented on the efficacy and safety of silymarin may provide more foundation for further trials and for a possible use in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study has been approved by the Research Ethics Committee of the Professor Edgard Santos University Hospital Complex, Salvador BA, Brazil, under protocol 2.635.954. The study is carried out according to guidelines and regulatory standards for research involving humans, as set out in Brazilian legislation. Trial registration - ClinicalTrials.gov : NCT03749070. November 21, 2018<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07210-6","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T14:04:24Z","timestamp":1678457064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of silymarin in patients with non-alcoholic fatty liver disease \u2014 the Siliver trial: a study protocol for a randomized controlled clinical trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-3723","authenticated-orcid":false,"given":"Camila Ribeiro","family":"de Avelar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Vieira Coelho","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"da Silva Sassaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"dos Santos Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucivalda Pereira Magalh\u00e3es","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Castro","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allain Amador","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e2ngela Passos","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"7210_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clinimag.2020.04.028","volume":"65","author":"M Cerit","year":"2020","unstructured":"Cerit M, \u015eendur HN, Cindil E, Erba\u015f G, Yal\u00e7\u0131n M, Cerit E, et al. Quantification of liver fat content with ultrasonographic attenuation measurement function: correlation with unenhanced multidimensional computerized tomography. Clin Imaging. 2020;65:85\u201393. https:\/\/doi.org\/10.1016\/j.clinimag.2020.04.028.","journal-title":"Clin Imaging"},{"issue":"6","key":"7210_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2036.2007.03426.x","volume":"26","author":"AA Dan","year":"2007","unstructured":"Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;26(6):815\u201320. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03426.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"7210_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/apt.12255","volume":"37","author":"MD Beaton","year":"2013","unstructured":"Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37(7):720\u20139. https:\/\/doi.org\/10.1111\/apt.12255.","journal-title":"Aliment Pharmacol Ther"},{"issue":"28","key":"7210_CR4","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.3748\/wjg.v20.i28.9338","volume":"20","author":"W Nseir","year":"2014","unstructured":"Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(28):9338\u201344. https:\/\/doi.org\/10.3748\/wjg.v20.i28.9338.","journal-title":"World J Gastroenterol"},{"key":"7210_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13293-022-00475-7","volume":"13","author":"S Fresneda","year":"2022","unstructured":"Fresneda S, Abbate M, Busquets-Cort\u00e9s C, L\u00f3pez-Gonz\u00e1lez A, Fuster-Parra P, Bennasar-Veny M, et al. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. Biol Sex Differ. 2022;13:64. https:\/\/doi.org\/10.1186\/s13293-022-00475-7.","journal-title":"Biol Sex Differ"},{"issue":"11","key":"7210_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1017\/S0007114514002591","volume":"112","author":"J Veena","year":"2014","unstructured":"Veena J, Muragundla A, Sidgiddi S, Subramaniam S. Non-alcoholic fatty liver disease: need for a balanced nutritional source. Br J Nutr. 2014;112(11):1858\u201372. https:\/\/doi.org\/10.1017\/S0007114514002591.","journal-title":"Br J Nutr"},{"issue":"6","key":"7210_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","volume":"9","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524\u201330. https:\/\/doi.org\/10.1016\/j.cgh.2011.03.020.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"7210_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","volume":"37","author":"S Bellentani","year":"2017","unstructured":"Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81\u20134. https:\/\/doi.org\/10.1111\/liv.13299.","journal-title":"Liver Int"},{"issue":"1","key":"7210_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","volume":"12","author":"JG Fan","year":"2011","unstructured":"Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis. 2011;12(1):38\u201344. https:\/\/doi.org\/10.1111\/j.1751-2980.2010.00476.x.","journal-title":"J Dig Dis"},{"issue":"1","key":"7210_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jgh.13856","volume":"33","author":"S Chitturi","year":"2018","unstructured":"Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, et al. The Asia\u2013Pacific working party on non-alcoholic fatty liver disease guidelines 2017\u2014part 2: management and special groups. J Gastroenterol Hepatol. 2018;33(1):86\u201398. https:\/\/doi.org\/10.1111\/jgh.13856.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"7210_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/1751-2980.12685","volume":"20","author":"JG Fan","year":"2019","unstructured":"Fan JG, Wei L, Zhuang H. National workshop on fatty liver and alcoholic liver disease, Chinese society of hepatology, Chinese medical association; fatty liver disease expert committee, Chinese medical doctor association. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. 2019;20(4):163\u201373. https:\/\/doi.org\/10.1111\/1751-2980.12685.","journal-title":"J Dig Dis"},{"issue":"4","key":"7210_CR12","first-page":"265","volume":"9","author":"SJ Hashemi","year":"2009","unstructured":"Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon. 2009;9(4):265\u201370 https:\/\/brief.land\/hepatmon\/articles\/69944.html.","journal-title":"Hepat Mon"},{"issue":"3","key":"7210_CR13","first-page":"181","volume":"18","author":"M Masoodi","year":"2013","unstructured":"Masoodi M, Rezadoost AM, Panahian M, Vojdanian M. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases. Govaresh. 2013;18(3):181\u20135 http:\/\/www.govaresh.org\/index.php\/dd\/article\/view\/1263.","journal-title":"Govaresh"},{"issue":"1","key":"7210_CR14","first-page":"9","volume":"5","author":"H Solhi","year":"2014","unstructured":"Solhi H, Ghahremani R, Kazemifar AM, Hoseini YZ. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med. 2014;5(1):9\u201312 PMID: 24490006; PMCID: PMC3894463.","journal-title":"Caspian J Intern Med"},{"issue":"11","key":"7210_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1089\/jir.2017.0051","volume":"37","author":"WF Fathalah","year":"2017","unstructured":"Fathalah WF, Abdel Aziz MA, Abou El Soud NH, El Raziky MES. High dose of silymarin in patients with decompensated liver disease: A randomized controlled trial. J Interf Cytokine Res. 2017;37(11):480\u20137. https:\/\/doi.org\/10.1089\/jir.2017.0051.","journal-title":"J Interf Cytokine Res"},{"issue":"27","key":"7210_CR16","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.3748\/wjg.v23.i27.5004","volume":"23","author":"CR De Avelar","year":"2017","unstructured":"De Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol. 2017;23(27):5004\u201317. https:\/\/doi.org\/10.3748\/wjg.v23.i27.5004.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"7210_CR17","first-page":"1285","volume":"72","author":"F Rainone","year":"2005","unstructured":"Rainone F. Milk thistle. Am Fam Physician. 2005;72(7):1285\u20138 https:\/\/www.aafp.org\/afp\/2005\/1001\/p1285.html.","journal-title":"Am Fam Physician"},{"issue":"1","key":"7210_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000113648","volume":"15","author":"R Saller","year":"2008","unstructured":"Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15(1):9\u201320. https:\/\/doi.org\/10.1159\/000113648.","journal-title":"Forsch Komplementmed"},{"issue":"3","key":"7210_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1574887109666141216110337","volume":"9","author":"N Milosevic","year":"2014","unstructured":"Milosevic N, Milanovic M, Abenavoli L, Natasa M. Phytotherapy and NAFLD \u2013 from goals and challenges to clinical practice. Rev Recent Clin Trials. 2014;9(3):195\u2013203. https:\/\/doi.org\/10.2174\/1574887109666141216110337.","journal-title":"Rev Recent Clin Trials"},{"key":"7210_CR20","doi-asserted-by":"publisher","unstructured":"Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and tolerance of silymarin (Milk Thistle) in chronic hepatitis C virus infection patients: A meta-analysis of randomized controlled trials. Biomed Res Int. 2014:941085. https:\/\/doi.org\/10.1155\/2014\/941085.","DOI":"10.1155\/2014\/941085"},{"issue":"12","key":"7210_CR21","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1124\/dmd.111.040212","volume":"39","author":"SJ Schrieber","year":"2011","unstructured":"Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011;39(12):2182\u201390. https:\/\/doi.org\/10.1124\/dmd.111.040212.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"7210_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0168-8278(97)80255-3","volume":"26","author":"M Velussi","year":"1997","unstructured":"Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26(4):871\u20139. https:\/\/doi.org\/10.1016\/S0168-8278(97)80255-3.","journal-title":"J Hepatol"},{"issue":"3","key":"7210_CR23","first-page":"191","volume":"8","author":"AA Hajaghamohammadi","year":"2008","unstructured":"Hajaghamohammadi AA, Ziaee A, Raflei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease. A randomized controlled clinical trial. Hepat Mon. 2008;8(3):191\u20135 https:\/\/brief.land\/hepatmon\/articles\/70029.html.","journal-title":"Hepat Mon"},{"issue":"5","key":"7210_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.phymed.2009.02.002","volume":"16","author":"SS El-Kamary","year":"2009","unstructured":"El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009;16(5):391\u2013400. https:\/\/doi.org\/10.1016\/j.phymed.2009.02.002.","journal-title":"Phytomedicine"},{"issue":"6","key":"7210_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/s0002-9343(02)01244-5","volume":"113","author":"BP Jacobs","year":"2002","unstructured":"Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002;113(6):506\u201315. https:\/\/doi.org\/10.1016\/s0002-9343(02)01244-5.","journal-title":"Am J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07210-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T14:06:05Z","timestamp":1678457165000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07210-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7210"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07210-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of the Professor Edgard Santos University Hospital Complex under application protocol 2.635.954. Patients eligible to join the trial were invited to sign the consent form after receiving all the information regarding the trial, including potential risks, and after having their questions answered in full. Participants signed two copies of the consent form; one copy will remain with the participant and the other with the researcher.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"All participants have consented on their data to be analyzed and published in an anonymized format. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"177"}}